ATE398464T1 - Synergie zwischen apo-2 ligand und antikörper gegen her-2 - Google Patents

Synergie zwischen apo-2 ligand und antikörper gegen her-2

Info

Publication number
ATE398464T1
ATE398464T1 AT99915054T AT99915054T ATE398464T1 AT E398464 T1 ATE398464 T1 AT E398464T1 AT 99915054 T AT99915054 T AT 99915054T AT 99915054 T AT99915054 T AT 99915054T AT E398464 T1 ATE398464 T1 AT E398464T1
Authority
AT
Austria
Prior art keywords
apo
ligand
synergy
antibodies against
antibodies
Prior art date
Application number
AT99915054T
Other languages
English (en)
Inventor
Avi Ashkenazi
Gail Phillips
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE398464T1 publication Critical patent/ATE398464T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT99915054T 1998-03-27 1999-03-26 Synergie zwischen apo-2 ligand und antikörper gegen her-2 ATE398464T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7968398P 1998-03-27 1998-03-27

Publications (1)

Publication Number Publication Date
ATE398464T1 true ATE398464T1 (de) 2008-07-15

Family

ID=22152138

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99915054T ATE398464T1 (de) 1998-03-27 1999-03-26 Synergie zwischen apo-2 ligand und antikörper gegen her-2

Country Status (13)

Country Link
US (5) US20020141993A1 (de)
EP (1) EP1064027B1 (de)
JP (2) JP2002507404A (de)
AT (1) ATE398464T1 (de)
AU (3) AU765003B2 (de)
CA (1) CA2324494A1 (de)
CY (1) CY1108320T1 (de)
DE (1) DE69938923D1 (de)
DK (1) DK1064027T3 (de)
ES (1) ES2308836T3 (de)
IL (2) IL138034A0 (de)
PT (1) PT1064027E (de)
WO (1) WO1999048527A1 (de)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6284236B1 (en) 1995-06-29 2001-09-04 Immunex Corporation Cytokine that induces apoptosis
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US20040013667A1 (en) * 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US20030086924A1 (en) * 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
TR200200472T2 (tr) 1999-08-27 2002-06-21 Genentech, Inc. Anti-Erb B2 antikorları ile tedavi için dozajlar
KR20020073181A (ko) 2000-01-25 2002-09-19 제넨테크, 인크. Ｌｉｖ-1 관련 단백질, 이를 코딩하는 폴리뉴클레오티드및 암의 치료를 위한 그의 용도
EP1280923A2 (de) * 2000-04-28 2003-02-05 Millennium Pharmaceuticals, Inc. 14094, ein angehörige der menschlichen trypsin-familie, und dessen verwendungen
CN104383535A (zh) 2000-05-19 2015-03-04 杰南技术公司 用于提高对ErbB拮抗剂癌症治疗的有效应答可能性的基因检测试验
DE10034607A1 (de) * 2000-07-20 2002-02-07 Gundram Jung Multispezifisches Reagenz zur selektiven Stimulierung von Zelloberflächenrezeptoren
EP1303293B1 (de) * 2000-07-27 2008-12-03 Genentech, Inc. Sequentielle verabreichung von cpt-11 und apo-2l polypeptid
US20030228309A1 (en) * 2000-11-08 2003-12-11 Theodora Salcedo Antibodies that immunospecifically bind to TRAIL receptors
US20060062786A1 (en) * 2000-11-08 2006-03-23 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US20050214209A1 (en) * 2001-05-25 2005-09-29 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US20050129616A1 (en) * 2001-05-25 2005-06-16 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US7361341B2 (en) * 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
US7741285B2 (en) 2001-11-13 2010-06-22 Genentech, Inc. APO-2 ligand/trail formulations
DK1450847T3 (da) 2001-11-13 2010-12-13 Genentech Inc Apo2-ligand/TRAIL-formuleringer og anvendelser deraf
CA2471140A1 (en) * 2001-12-20 2003-07-03 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
JP2007536254A (ja) * 2004-05-05 2007-12-13 メリマック ファーマシューティカルズ インコーポレーティッド 生物活性を調節するための二重特異性結合剤
GT200500155A (es) * 2004-06-16 2006-05-15 Terapia del càncer resistente al platino
ZA200701234B (en) 2004-07-22 2008-12-31 Genentech Inc HER2 antibody composition
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
WO2006063042A2 (en) * 2004-12-07 2006-06-15 Genentech, Inc. Selecting patients for therapy with a her inhibitor
CA2592177A1 (en) 2005-01-21 2006-07-27 Genentech, Inc. Fixed dosing of her antibodies
ZA200707078B (en) * 2005-02-23 2008-11-26 Genentech Inc Extending time to disease progression or survival in cancer patients
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
PE20070207A1 (es) 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
EP2522352B1 (de) 2006-03-02 2017-01-11 Agency for Science, Technology and Research Verfahren zur Stammzellenmodulation
DK2132573T3 (da) 2007-03-02 2014-07-14 Genentech Inc Forudsigelse af respons på en her-dimeriseringsinhibitor på basis af lav her3-ekspression
US8557588B2 (en) * 2007-03-27 2013-10-15 Schlumberger Technology Corporation Methods and apparatus for sampling and diluting concentrated emulsions
CA2917355C (en) * 2007-06-08 2018-07-17 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
CN101909630A (zh) * 2007-11-02 2010-12-08 新加坡科技研究局 预防和治疗肿瘤的方法和化合物
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
WO2010108127A1 (en) 2009-03-20 2010-09-23 Genentech, Inc. Bispecific anti-her antibodies
SG10201507044PA (en) 2009-05-29 2015-10-29 Hoffmann La Roche Modulators for her2 signaling in her2 expressing patients with gastric cancer
RU2609658C2 (ru) * 2009-12-21 2017-02-02 Дженентек, Инк. Состав, содержащий антитело
US9556249B2 (en) 2010-02-18 2017-01-31 Genentech, Inc. Neuregulin antagonists and use thereof in treating cancer
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
JP6082344B2 (ja) 2010-05-27 2017-02-15 ゲンマブ エー／エス Ｈｅｒ２エピトープに対するモノクローナル抗体
CN114805583A (zh) 2010-05-27 2022-07-29 根马布股份公司 针对her2的单克隆抗体
US20130245233A1 (en) 2010-11-24 2013-09-19 Ming Lei Multispecific Molecules
EP2655413B1 (de) 2010-12-23 2019-01-16 F.Hoffmann-La Roche Ag Polypeptid-polynukleotid-komplex und verwendung bei der gezielten effektorrest-bereitstellung
WO2012143524A2 (en) 2011-04-20 2012-10-26 Genmab A/S Bispecific antibodies against her2 and cd3
US20140363438A1 (en) 2011-08-17 2014-12-11 Genentech, Inc. Neuregulin antibodies and uses thereof
BR112014007521A8 (pt) 2011-10-14 2018-04-10 Genentech Inc método para estender a sobrevida livre de progressão em uma população com câncer de mama, artigo de fabricação, método para produção de um artigo de fabricação, para garantir o uso seguro e efetivo de pertuzumabe, de tratar câncer de mama, bolsa intravenosa, método de tratar câncer gástrico, de tratar adenocarcinoma do estômago e de melhora de sobrevida
WO2013063229A1 (en) 2011-10-25 2013-05-02 The Regents Of The University Of Michigan Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells
EP2785864A2 (de) 2011-11-30 2014-10-08 F. Hoffmann-La Roche AG Erbb3-mutationen bei krebs
US9376715B2 (en) 2011-12-09 2016-06-28 Roche Molecular Systems, Inc Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene
AU2013240261A1 (en) 2012-03-27 2014-09-18 Genentech, Inc. Diagnosis and treatments relating to HER3 inhibitors
IN2014DN09417A (de) 2012-05-10 2015-07-17 Bioatla Llc
CA2889298C (en) 2012-11-30 2024-01-02 Anton Belousov Identification of patients in need of pd-l1 inhibitor cotherapy
AR095863A1 (es) 2013-04-16 2015-11-18 Genentech Inc Variantes de pertuzumab, su evaluación, método de tratamiento, método de preparación y artículo de fabricación
EP3581586A1 (de) 2014-04-25 2019-12-18 F. Hoffmann-La Roche AG Verfahren zur behandlung von frühzeitigem brustkrebs mit trastuzumab-mcc-dm1 und pertuzumab
TWI758784B (zh) 2014-09-12 2022-03-21 美商建南德克公司 抗her2抗體及免疫結合物
HK1243629A1 (zh) * 2014-09-17 2018-07-20 基因泰克公司 包含抗her2抗体和吡咯并苯并二氮杂䓬的免疫缀合物
LT3302551T (lt) 2015-05-30 2024-09-10 F. Hoffmann-La Roche Ag Anksčiau negydyto metastazavusio her2 teigiamo krūties vėžio gydymo būdai
AU2016331931C1 (en) 2015-10-02 2020-01-16 Genentech, Inc. Pyrrolobenzodiazepine antibody drug conjugates and methods of use
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
WO2017194554A1 (en) 2016-05-10 2017-11-16 Inserm (Institut National De La Sante Et De La Recherche Medicale) Combinations therapies for the treatment of cancer
TW201818940A (zh) 2016-11-04 2018-06-01 美商建南德克公司 Her2陽性乳癌之治療
CN110099926A (zh) 2016-12-28 2019-08-06 豪夫迈·罗氏有限公司 晚期her2表达性癌症的治疗
KR20210134432A (ko) 2017-01-17 2021-11-09 제넨테크, 인크. 피하 her 2 항체 제형
CN110337450B (zh) 2017-03-02 2023-07-25 豪夫迈·罗氏有限公司 Her2阳性乳腺癌的辅助治疗
CN110536969A (zh) 2017-04-24 2019-12-03 豪夫迈·罗氏有限公司 跨膜或近膜域中的erbb2/her2突变
CN112513081A (zh) 2018-06-14 2021-03-16 生物蛋白有限公司 多重特异性抗体构建体
IL299376A (en) 2020-06-29 2023-02-01 Genentech Inc Fixed dose combination of pertuzumab plus transtuzumab

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5720937A (en) * 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DE69228300T2 (de) * 1991-08-22 1999-09-23 Becton Dickinson And Co., Franklin Lakes Methoden und zusammensetzungen zur krebstherapie und zur vorhersagbarkeit der reaktionen auf diese behandlung
FI941572A7 (fi) * 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
ES2253753T3 (es) * 1995-06-29 2006-06-01 Immunex Corporation Citocina que induce apoptosis.
US5783186A (en) * 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US6030945A (en) * 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
CA2301202A1 (en) * 1997-08-15 1999-02-25 Idun Pharmaceuticals, Inc. Trail receptors, nucleic acids encoding the same, and methods of use thereof

Also Published As

Publication number Publication date
PT1064027E (pt) 2008-09-29
AU3365999A (en) 1999-10-18
US20050244417A1 (en) 2005-11-03
EP1064027B1 (de) 2008-06-18
CY1108320T1 (el) 2014-02-12
US20080241146A1 (en) 2008-10-02
EP1064027A1 (de) 2001-01-03
DK1064027T3 (da) 2008-09-08
US20080160026A1 (en) 2008-07-03
HK1034040A1 (en) 2001-10-12
CA2324494A1 (en) 1999-09-30
IL138034A (en) 2007-12-03
DE69938923D1 (de) 2008-07-31
AU2010201871A1 (en) 2010-05-27
AU2003266765A1 (en) 2004-01-15
IL138034A0 (en) 2001-10-31
JP2002507404A (ja) 2002-03-12
AU765003B2 (en) 2003-09-04
JP2010088438A (ja) 2010-04-22
US20020141993A1 (en) 2002-10-03
ES2308836T3 (es) 2008-12-01
US20070026001A1 (en) 2007-02-01
WO1999048527A1 (en) 1999-09-30

Similar Documents

Publication Publication Date Title
ATE398464T1 (de) Synergie zwischen apo-2 ligand und antikörper gegen her-2
DE60028971D1 (de) Apo-2l rezeptor-agonist und cpt-11 synergie-effekt
DK1261601T3 (da) Substituerede indoler til modulering af NFKB-aktivitet
ATE216879T1 (de) Verwendung von benzhydrylsulfinylderivaten zur behandlung der schläfigkeit medikamentösen ursprungs
EA200900272A1 (ru) Комбинации для лечения заболеваний, связанных с клеточной пролиферацией, миграцией или апоптозом клеток миеломы или с ангиогенезом
BR9707233A (pt) Fenantridinas
DK1096924T3 (da) Inhibitorer af proteasomal aktivitet til stimulering af hårvækst
ATE113837T1 (de) Mittel zur bekämpfung des schmerzes, der depression und zur beruhigung.
DE60322102D1 (de) Transdermales buprenorphin-dosierschema zwecks schmerzstillung
DE69813839D1 (de) Verwendung von n,n-bis (phenylcarbamoylmethyl) dimethylammoniumchlorid und derivaten davon zur behandlung von chronischem schmerz
DK1235571T3 (da) Anvendelse af melatonin til behandling af androgenetisk eller diffus alopecia af feminin type
WO2000046187A3 (en) Antizyme modulators and their use
DE60124387D1 (de) Synergistische kombination zur behandlung von kolorektalkarzinom
TR200103634T2 (tr) Bitkilerde flavonoidlerin ve fenolik maddelerin miktarını arttırma yöntemi.
DK1689404T3 (da) Kombination af et-743 med 5-fluoracil-prodrugs til behandling af cancer
DK1001775T3 (da) Medikament indeholdende yohimbin og arginin beregnet til behandling af erektil dysfunktion
ATE285247T1 (de) Krebstherapie mit lymphotoxin
ATE293972T1 (de) Behandlung von chronischen schmerzen
DE59808313D1 (de) Verwendung von wirkstoffkombinationen aus antibiotika und terpenhaltigen pflanzenextrakten in der tiermedizin
AUPP379698A0 (en) Using ngali nut oil to treat/relieve the pain of arthritis and other similar conditions
TR200002939T2 (tr) Paroksetin maleat
ATE371446T1 (de) Zusammensetzungen zur verhinderung der adhäsion
FI965171L (fi) Oksatsofosforiinien, esimerkiksi ifosfamidin, enantiomeerien käyttö kasvainten hoidossa sivuvaikutuksien vähentämiseksi
ATE309808T1 (de) Ex vivo behandlung von allogenen und xenogenen t- zellen mit gp39-antagonisten
ID23210A (id) Komposisi sinergistik dan metoda untuk pengobatan neoplastik atau pertumbuhan kanker dan untuk memperbaiki atau meningkatkan hematopoiesis

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1064027

Country of ref document: EP

REN Ceased due to non-payment of the annual fee